Abstract
Overview
Introduction
As advances in omics technologies enable the development of high value
molecular diagnostics, neurological conditions represent an attractive target
for diagnostic companies. In this report, Datamonitor identifies the diseases
in which early detection with a biomarker could significantly benefit the
patient, gain payer approval, and ultimately expand the pharmaceutical market.
Scope
- Neurological conditions covered: Alzheimer' s disease, Parkinson' s disease,
MS, epilepsy, migraine, insomnia, Huntington' s disease and ALS.
- Overview of key biomarkers in development for each condition (including
genetics).
- Identification of key factors required for the commercial success of
neurological diagnostic biomarkers.
- Analysis of potential drug revenue gains due to improved diagnostics in
Alzheimer' s disease.
Highlights
A battery or algorithm of tests for each disease is likely to be available
within the next 10 years. This is already the case for multiple sclerosis, the
most mature neurological diagnostic market, with both clinical, imaging and in
vitro diagnostics incorporated in a clear algorithm.
Revenue gained from earlier use (identification and incorporation of mild
cognitively impaired patients) of potentially disease-modifying drugs in
Alzheimer' s disease could generate an additional $5 billion by 2017 across the
seven major markets (US, Japan, France, Germany, Italy, Spain and the UK).
Neurology biomarker discovery and development is an attractive market for
small biotechnology companies. The regulation of in vitro diagnostics is
significantly less stringent than for pharmaceutical drugs. This decreases the
considerable financial barriers to entry usually faced by biotechnology
companies orientated towards drug discovery.
Reasons to Purchase
- Assess which diseases have the highest unmet need for new biomarkers.
- Appreciate the lucrative potential of earlier treatment of
neurodegenerative conditions.
- Forecast the impact of improved diagnostics on neurological drug sales.